Insider Trading Tue 3/12/24

Notable purchases -- Chief R&D Officer adds to KDP; notable sales -- CBO active in RARE

Buyers:

• CRBP 10% owner Cormorant Asset Management bought 550,000 shares at $37.53 - $46.00 worth ~$23.3 mln.
• CSV Director bought 5,000 shares at $26.10 worth ~$131K.
• FGEN CEO bought 50,000 shares at $1.9094 worth ~$95K.
• HWBK Director bought 5,000 shares at $19.90 - $20.645 worth ~$102K.
• KDP Chief R&D Officer bought 4,075 shares at $29.11 worth ~$119K.
• MOFG CEO bought 4,447 shares at $22.4866 worth ~$100K.

Sellers:

• ATR Segment President and one (1) Director sold 5,500 shares combined worth ~$785K.
• LKFN EVP sold 5,247 shares at $66.75 worth ~$350K.
• MDC Director sold 6,200 shares at $62.69 worth ~$389K.
• RARE Chief Business Officer & EVP sold 11,509 shares at $49.92 - $50.06 worth ~$575K.
• USNA Executive Chairman and COO sold 16,251 shares combined at $48.98 - $49.16 worth ~$797K.

=Ultragenyx (RARE) : muscle-disease drug study fails

Ultragenyx Pharma announces its Phase 3 study evaluating aceneuramic acid extended release in patients with GNE Myopathy did not achieve its primary endpoint; co will discontinue further development --halted--(58.85 +1.94)
The Phase 3 study evaluating aceneuramic acid extended release (Ace-ER) in patients with GNE Myopathy (GNEM) did not achieve its primary endpoint of demonstrating a statistically significant difference in the upper extremity muscle strength composite score compared to placebo. The study also did not meet its key secondary endpoints. Adverse events were generally balanced between Ace-ER and placebo and safety was consistent with previously released Ace-ER data. Ultragenyx plans to discontinue further clinical development of Ace-ER.